Abstract
Introduction: Medication related osteonecrosis of the jaw (MRONJ) adversely affects quality of life, producing significant morbidity. MRONJ is reported in patients taking oral and intravenous bisphosphonates as potent inhibitors of bone resorption. Concomitant use with newer medications such as RANKL inhibitors and anti-angiogenic medications also predispose to the development of jaw osteonecrosis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
